-
Proton pump inhibitors or increase the risk of type 2 diabetes, the longer the course of treatment, the higher the risk! 2022EASD
Time of Update: 2022-10-02
Translator: Wensi Yichang Traditional Chinese Medicine Hospital (Affiliated Traditional Chinese Medicine Hospital of China Three Gorges University)Introduction: From September 19 to 23, 2022, the inte
-
China's first domestic proton therapy system was approved for listing
Time of Update: 2022-10-01
docx In recent years, the State Drug Administration has fully implemented the requirements of the Party Central Committee and the State Council on deepening the reform of the medical device review and approval system, actively promoted the listing of innovative medical devices, national key research and development plans and major scientific and technological special medical devices, promoted the high-quality development of industrial innovation, and better met the health needs of patients.
-
The domestic proton therapy system was approved for use and its performance was comparable to that of imported similar devices
Time of Update: 2022-09-30
The reporter learned on the 27th that the State Drug Administration approved the application for registration of innovative products of "proton therapy system" produced by Shanghai enterprises. In th
-
1426827-79-3, Endo-BCN nitrobenzene is a proton connectome
Time of Update: 2022-09-21
, Ltd. storeview four, other products D-mannoseamine hydrochloride, D-Mannosamine Hydrochloride, CAS: 5505-63-5 allyl-Α-D-galactopyranoside, Ally α-D-Galactopyranoside,CAS:48149-72-03,4,6-O-Triacetyl-D-Galactostene,D-Triacetyl Galactene,3,4,6-Tri-O-acetyl-D-galactal,CAS:4098-06-01,2,3,4,6-Five-O-acetyl-β-D-galactose,1,2,3,4,6- Penta-O-acetyl-β-D-galactopyranose,CAS:4163-60-42,3,4,6-tetraacetyloxy-alpha-D-pyranosacide bromide,2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl Bromide,CAS:3068-32-44-nitrophenyl-α-D-galactogalactoside,4- Nitrophenyl α-D-galactopyranoside, CAS: 7493-95-01,3,4,6-tetra-O-acetyl-N-azidoacetylaminomanose, N-azidoacetylmannosamine-tetraacylated (Ac4ManNAz), CAS: 361154-30-5First, the product introduction click ring addition reaction is a very efficient and reliable bio-binding process, 5'-Click-easy BCN-CE phosphamide can be used to prepare oligonucleotides and copper-free click ring addition.
-
The latest retrospective study on proton therapy for esophageal cancer uses actual data to give
Time of Update: 2022-09-14
▲ 5-year survival rate of proton treatment for esophageal cancer,03A 2020 randomized study compared the total toxic burden (TTB) and survival of intensity-modulated radiotherapy (IMRT) and proton therapy.
-
Proton Bio and Ruotai Announce Strategic Cooperation to Accelerate the Development of Bacterial Drugs and mRNA Drugs
Time of Update: 2022-09-10
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
-
Proton pump inhibitors must be used with caution during tumor treatment!
Time of Update: 2022-09-06
The following guidelines for the preventive use of PPIs also make clear restrictionsThe "Expert Consensus on Proton Pump Inhibitor Prophylactic Application 2018" pointed out that short-term intravenous application of PPIs can be used in cancer patients when intravenous chemotherapy drugs with the risk of emesis are used .
-
Ultra-high survival rate and disease control rate, proton heavy ion precision radiotherapy can
Time of Update: 2022-08-19
▲ Source: reference source [1]Proton heavy ion treatment of osteosarcoma has a control rate of 92%In 2017, a clinical study conducted by Japanese researchers and published in "Int J Radiat Oncol Biol Phys" analyzed the effect of proton-heavy ion therapy on bone and soft tissue tumors.
-
JGH: Long-term use of proton pump inhibitors increases risk of osteoporosis and hip fractures
Time of Update: 2022-08-11
Leave a Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data model.
Leave a Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data model.
-
Proton Bio and Biopharma Announce Strategic Cooperation to Accelerate the Development of Solid Tumor Cell Therapy Drugs
Time of Update: 2022-06-05
Hu Pingsheng, founder of Shengnuo Pharmaceutical, said : "The strategic cooperation between Shengnuo Pharmaceutical and Proton Bio will promote the development of new solid tumor immune cell drugs and accelerate the clinical research of a series of pipelines.
-
JCEM: Association of long-term proton pump inhibitor use with risk of type 2 diabetes
Time of Update: 2022-05-09
Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study .
1210/clinem/dgac231/6569190Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study
-
Dig Dis Sci: Inappropriate use of proton pump inhibitors after discharge is associated with increased readmission rates
Time of Update: 2022-04-23
A logistic regression model was used to estimate the 30-day odds of readmission for inappropriately discharged patients compared with appropriate new PPIs .
This study demonstrated that inappropriate PPI discharge was associated with 30-day readmission compared with appropriate PPI .
-
J Thorac Oncol: Pooled analysis of 5 RCTs suggests that proton pump inhibitor (PPIs) use reduces the efficacy of atezolizumab treatment
Time of Update: 2022-04-23
Therefore, the Australian team conducted a pooled analysis study to assess whether antibiotics or PPIs affected the efficacy of atezolizumab ( atezolizumab ) in patients with advanced non-small cell lung cancer (NSCLC) .
-
Nature sub-journal: Laser-accelerated proton beam irradiation for tumor therapy
Time of Update: 2022-04-22
The research team constructed a research platform that enables ultra-high peak dose rate irradiation of tumors in small animal models using a proton beam from a laser plasma accelerator .
-
The world's leading hydrogen fuel cell proton exchange membrane is put into production in Dongyue
Time of Update: 2022-03-14
5 million square meters proton exchange membrane production line of Dongyue Group, which has attracted much attention from the industry and the whole society, was put into operation in Zibo, which marked that the production scale of the proton exchange membrane, the core material of hydrogen fuel cells in China, reached The world's leading level.